Vanda Pharmaceuticals Inc. (VNDA) P/E Ratio History
Historical price-to-earnings valuation from 2010 to 2023
Loading P/E history...
VNDA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Vanda Pharmaceuticals Inc. (VNDA) trades at a price-to-earnings ratio of -1.7x, with a stock price of $6.39 and trailing twelve-month earnings per share of $-4.03.
The current P/E is 105% below its 5-year average of 34.4x. Over the past five years, VNDA's P/E has ranged from a low of 4.8x to a high of 96.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, VNDA trades at a 108% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, VNDA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VNDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VNDA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 8.3 | - | +264% | |
| $4B | 9.9 | - | +68% | |
| $2B | 6.9Lowest | 0.67 | +817%Best | |
| $930M | 147.8 | - | +107% | |
| $8B | 25.5 | 1.11 | -25% | |
| $2B | 68.8 | - | +194% | |
| $3B | 11.4 | 0.07Best | +40% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
VNDA Historical P/E Data (2010–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $4.22 | $0.04 | 96.6x | -7% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $4.32 | $0.21 | 21.0x | -80% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $6.59 | $0.26 | 25.3x | -76% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $6.79 | $0.28 | 24.3x | -77% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $7.39 | $0.11 | 65.6x | -37% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $9.88 | $0.11 | 87.7x | -16% |
| FY2022 Q2 | $10.90 | $0.20 | 55.8x | -47% | |
| FY2022 Q1 | $11.31 | $0.32 | 35.3x | -66% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $15.69 | $0.58 | 27.1x | -74% |
| FY2021 Q3 | $17.14 | $0.60 | 28.6x | -73% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $21.51 | $0.57 | 37.7x | -64% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $15.02 | $0.56 | 26.8x | -74% |
Average P/E for displayed period: 104.3x
See VNDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VNDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VNDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVNDA — Frequently Asked Questions
Quick answers to the most common questions about buying VNDA stock.
Is VNDA stock overvalued or undervalued?
VNDA trades at -1.7x P/E, below its 5-year average of 34.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does VNDA's valuation compare to peers?
Vanda Pharmaceuticals Inc. P/E of -1.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is VNDA's PEG ratio?
VNDA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2010-2023.